-
Takeda R&D Exec Explains How $1.2B Deal Could Become One of the Biggest Bargains in Drug History
16 Jan 2026 04:43 GMT
… fill their pipelines with new drugs offering blockbuster potential. A … non-small cell lung cancer drug failed the confirmatory study … the immune response. The drug simultaneously activates the IL-2 … The 2024 FDA approval of Astellas Pharma’s Vyloy in gastric …
-
JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears
15 Jan 2026 21:38 GMT
… Healthcare Conference.
However, Astellas recently downgraded its Izervay sales … Astellas is trying to focus on the part of the drug … Astellas needs to educate retinal specialists about the drug’ … hovering over Astellas is changing U.S. drug pricing policy. …
-
Ocugen sets sights on Phase III after GA gene therapy win
16 Jan 2026 17:03 GMT
… Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) and Astellas Pharma’s Iservay (avacincaptad pegol … -Related Macular Degeneration: Seven-Market Drug Forecast and Market Analysis report …
-
Fierce Pharma Asia—AbbVie’s bispecific play, Illumina’s China import efforts and pharma execs’ JPM comments
16 Jan 2026 15:18 GMT
… more “predictable” year in 2026.
Astellas CEO Naoki Okamura is keenly … and innovation mindset” of Chinese drug regulators.
Speaking of the rapid …
-
[JPM 2026] ABL Bio shifts beyond license-outs to build clinical-stage value, CEO says
16 Jan 2026 06:09 GMT
… clinical development capabilities for new drugs and creating sustainable value through … .
Recent phase 3 data for Astellas's zolbetuximab (sold as …
-
PADCEV▼ (enfortumab vedotin) Plus Keytruda Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
15 Jan 2026 10:18 GMT
… with muscle-invasive bladder cancer
Astellas Pharma Co. Ltd. recently … a Nectin-4 directed antibody-drug conjugate, in combination with … a first-in-class antibody-drug conjugate (ADC) that … al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is …
-
<![CDATA[utDNA and ctDNA Are Predictive of Residual Disease After TAR-200 in MIBC]]>
15 Jan 2026 04:39 GMT
… checkpoint inhibitors [ICIs] or other drugs that are approved in this … , and starting to add other drugs—systemic therapy or intravesical therapy … consulting or advisory fees from Astellas, AstraZeneca, Bristol Myers Squibb, Catalym …
-
Bayer taps Gabrielle Union-Wade as face of menopause med Lynkuet
15 Jan 2026 01:58 GMT
… its newly launched nonhormonal menopause drug, Bayer is linking Lynkuet … comes in to list the drug’s uses, risks and … the third nonhormonal menopause symptom drug approved by the FDA. … to Bayer. Competitor Veozah, from Astellas Pharma, targets NK3, while …
-
Advancing Precision Medicine in Non-Small Cell Lung Cancer Diagnostics in a Southeast Asian Country
13 Jan 2026 09:37 GMT
… targeted therapies remain costly, these drugs could still be innovatively delivered … Sharp & Dohme, AB Science, Astellas, Tessa Therapeutics, Roche, Arcus Bioscience …
-
JPM26: Apellis shares tumble with sales decline for eye disease treatment Syfovre
13 Jan 2026 02:08 GMT
… of its geographic atrophy (GA) drug Syfovre came in at $587 … in GA. It is battling Astellas and its injected GA medicine … blood disorder and kidney disease drug pulled in $35 million in …
About
© 1995-2026